SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                                November 29, 2001
                             ----------------------
                                 Date of Report
                        (Date of earliest event reported)

                             WORLD DIAGNOSTICS INC.
          ------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

            Delaware                   000-27627               65-0742342
-------------------------------   -------------------   -----------------------
(State or other jurisdiction of       (Commission            (IRS Employer
        incorporation)                File Number)        Identification No.)

               15271 N.W. 60th Avenue, Miami Lakes, Florida 33014
          -------------------------------------------------------------
              (Address of registrant's principal executive offices)

                                 (305) 827-3304
                              --------------------
              (Registrant's telephone number, including area code)

                                       N/A
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)



<PAGE>


Forward Looking Statements.

            This Current Report contains "forward looking statements" which can
be identified by the use of forward-looking terminology such as "believes",
"could", "possibly", "probably", anticipates", "estimates", "projects",
"expects", "may", "will", or "should" or the negative thereof or other
variations thereon or comparable terminology. Such statements are subject to
certain risks, uncertainties, and assumptions. No assurances can be given that
the future results anticipated by the forward-looking statements will be
achieved. Among the key factors that have a direct bearing on such results
include, without limitation, the execution and delivery of a definitive
agreement between the parties, the effects of various governmental regulations,
the fluctuation of the direct costs and the costs and effectiveness of the
Company's operating strategy. Other factors could also cause actual results to
vary materially from the future results covered in such forward-looking
statements. Such forward-looking statements are subject to certain risks and
uncertainties.

ITEMS 5. OTHER EVENTS.

            On November 28, 2001 World Diagnostics Inc. (the "Company") signed a
letter of intent with Caldon Biotech, Inc. ("Caldon") for the creation of a
joint venture and an option for the Company to acquire Caldon. The joint venture
and the terms of such acquisition shall be embodied in a definitive agreement
(the "Agreement") which shall be executed by the parties within 30 days of the
date of the letter of intent.

            Joint Venture. Following the execution of the Agreement, Caldon
shall be the exclusive supplier to the Company of clinical chemistry reagents,
rapid tests and may include Elisa tests. Caldon shall supply such products at
agreed upon prices and delivery terms and will be subject to a penalty if it
fails to meet the terms thereof. The Company will agree not to purchase such
products from any other party. The Company will guarantee any lease payments not
made by Caldon in connection with equipment leased by Caldon necessary to
manufacture and supply the products to the Company. Until such time as the
acquisition of Caldon by the Company shall be completed, each of the parties
shall operate independently of each other.

            Possible Acquisition of Caldon. The Agreement will provide for an
exclusive option granted to the Company to acquire Caldon within one year from
the date of the Agreement. If the option is exercised and the acquisition is
consummated by the Company, Ram Aviravan will be elected to the Board of
Directors of the Company and will receive an employment agreement for a period
of three years, or until such time as the agreed upon payments for the
acquisition of Caldon by the Company have been met.

            For the terms and conditions of the letter of intent, reference is
made to such document attached hereto as Exhibit 10.10. All statements made
herein concerning the foregoing are qualified in their entirety by reference to
such Exhibit.


<PAGE>

ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(a)      Financial Statements of Business Acquired.

            N/A

(b)      Pro Forma Financial Information.

            N/A

(c)      Exhibits.

10.10    Letter of Intent dated as of November 28, 2001, by and between World
         Diagnostics Inc. and Caldon Biotech, Inc.

10.11    Press Release issued by World Diagnostics Inc. on November 29, 2001.



<PAGE>
                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                     WORLD DIAGNOSTICS, INC.

                                                     By: /s/ Ken Peters
                                                         --------------
                                                         Ken Peters
                                                         President

Date: December 4, 2001
[{"type": "8-K", "sequence": "1", "filename": "s15-2593_8k.txt", "description": "FORM 8-K", "secsgml_size_bytes": 5702}]
{"company-data": {"conformed-name": "WORLD DIAGNOSTICS INC", "cik": "0001066795", "assigned-sic": "3841", "irs-number": "650742342", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27627", "film-number": "1805657"}, "business-address": {"street1": "15271 N W 60TH AVE", "street2": "STE 201", "city": "MIAMI LAKES", "state": "FL", "zip": "33014", "phone": "3058273304"}, "mail-address": {"street1": "15271 N W 60TH AVE", "street2": "STE 201", "city": "MIAMI LAKES", "state": "FL", "zip": "33014"}}
SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                                November 29, 2001
                             ----------------------
                                 Date of Report
                        (Date of earliest event reported)

                             WORLD DIAGNOSTICS INC.
          ------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

            Delaware                   000-27627               65-0742342
-------------------------------   -------------------   -----------------------
(State or other jurisdiction of       (Commission            (IRS Employer
        incorporation)                File Number)        Identification No.)

               15271 N.W. 60th Avenue, Miami Lakes, Florida 33014
          -------------------------------------------------------------
              (Address of registrant's principal executive offices)

                                 (305) 827-3304
                              --------------------
              (Registrant's telephone number, including area code)

                                       N/A
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)
Forward Looking Statements.

            This Current Report contains "forward looking statements" which can
be identified by the use of forward-looking terminology such as "believes",
"could", "possibly", "probably", anticipates", "estimates", "projects",
"expects", "may", "will", or "should" or the negative thereof or other
variations thereon or comparable terminology. Such statements are subject to
certain risks, uncertainties, and assumptions. No assurances can be given that
the future results anticipated by the forward-looking statements will be
achieved. Among the key factors that have a direct bearing on such results
include, without limitation, the execution and delivery of a definitive
agreement between the parties, the effects of various governmental regulations,
the fluctuation of the direct costs and the costs and effectiveness of the
Company's operating strategy. Other factors could also cause actual results to
vary materially from the future results covered in such forward-looking
statements. Such forward-looking statements are subject to certain risks and
uncertainties.

ITEMS 5. OTHER EVENTS.

            On November 28, 2001 World Diagnostics Inc. (the "Company") signed a
letter of intent with Caldon Biotech, Inc. ("Caldon") for the creation of a
joint venture and an option for the Company to acquire Caldon. The joint venture
and the terms of such acquisition shall be embodied in a definitive agreement
(the "Agreement") which shall be executed by the parties within 30 days of the
date of the letter of intent.

            Joint Venture. Following the execution of the Agreement, Caldon
shall be the exclusive supplier to the Company of clinical chemistry reagents,
rapid tests and may include Elisa tests. Caldon shall supply such products at
agreed upon prices and delivery terms and will be subject to a penalty if it
fails to meet the terms thereof. The Company will agree not to purchase such
products from any other party. The Company will guarantee any lease payments not
made by Caldon in connection with equipment leased by Caldon necessary to
manufacture and supply the products to the Company. Until such time as the
acquisition of Caldon by the Company shall be completed, each of the parties
shall operate independently of each other.

            Possible Acquisition of Caldon. The Agreement will provide for an
exclusive option granted to the Company to acquire Caldon within one year from
the date of the Agreement. If the option is exercised and the acquisition is
consummated by the Company, Ram Aviravan will be elected to the Board of
Directors of the Company and will receive an employment agreement for a period
of three years, or until such time as the agreed upon payments for the
acquisition of Caldon by the Company have been met.

            For the terms and conditions of the letter of intent, reference is
made to such document attached hereto as Exhibit 10.10. All statements made
herein concerning the foregoing are qualified in their entirety by reference to
such Exhibit.
ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(a)      Financial Statements of Business Acquired.

            N/A

(b)      Pro Forma Financial Information.

            N/A

(c)      Exhibits.

10.10    Letter of Intent dated as of November 28, 2001, by and between World
         Diagnostics Inc. and Caldon Biotech, Inc.

10.11    Press Release issued by World Diagnostics Inc. on November 29, 2001.
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                     WORLD DIAGNOSTICS, INC.

                                                     By: /s/ Ken Peters
                                                         --------------
                                                         Ken Peters
                                                         President

Date: December 4, 2001